BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37357717)

  • 21. Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study.
    Meier N; Munch MW; Granholm A; Perner A; Hertz FB; Venkatesh B; Hammond NE; Li Q; De Bus L; De Waele J; Kauzonas E; Sjövall F; Møller MH; Helleberg M
    Acta Anaesthesiol Scand; 2024 Jul; 68(6):821-829. PubMed ID: 38549422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
    Hundeshagen G; Herndon DN; Capek KD; Branski LK; Voigt CD; Killion EA; Cambiaso-Daniel J; Sljivich M; De Crescenzo A; Mlcak RP; Kinsky MP; Finnerty CC; Norbury WB
    Crit Care; 2017 Dec; 21(1):318. PubMed ID: 29262848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams.
    Tai CH; Shao CH; Wang CC; Lin FJ; Wang JT; Wu CC
    J Antimicrob Chemother; 2021 Jan; 76(2):499-506. PubMed ID: 33152760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperacillin/Tazobactam and Antibiotic-Associated Acute Kidney Injury in Critically Ill Children.
    Joyce EL; Kane-Gill SL; Priyanka P; Fuhrman DY; Kellum JA
    J Am Soc Nephrol; 2019 Nov; 30(11):2243-2251. PubMed ID: 31501354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury.
    Tang Girdwood S; Hasson D; Caldwell JT; Slagle C; Dong S; Fei L; Tang P; Vinks AA; Kaplan J; Goldstein SL
    J Antimicrob Chemother; 2023 Feb; 78(2):478-487. PubMed ID: 36545869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.
    Luther MK; Timbrook TT; Caffrey AR; Dosa D; Lodise TP; LaPlante KL
    Crit Care Med; 2018 Jan; 46(1):12-20. PubMed ID: 29088001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit.
    Buckley MS; Hartsock NC; Berry AJ; Bikin DS; Richards EC; Yerondopoulos MJ; Kobic E; Wicks LM; Hammond DA
    J Crit Care; 2018 Dec; 48():32-38. PubMed ID: 30172962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Kidney Injury in Hematopoietic Cell Transplantation Patients Receiving Vancomycin and Piperacillin/Tazobactam Versus Vancomycin and Cefepime.
    Clemmons AB; Bech CF; Pantin J; Ahmad I
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):820-826. PubMed ID: 29292056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
    Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
    Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney Injury in Critically Ill Patients Treated with Vancomycin and Zosyn or an Alternative: A Systematic Review and Meta-Analysis.
    Blears EE; Morris J; Popp D; Lee JO; Norbury WB
    Surg Infect (Larchmt); 2022 Aug; 23(6):516-524. PubMed ID: 35736797
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous magnesium sulfate for prevention of vancomycin plus piperacillin-tazobactam induced acute kidney injury in critically ill patients: An open-label, placebo-controlled, randomized clinical trial.
    Khalili H; Rahmani H; Mohammadi M; Salehi M; Mostafavi Z
    Daru; 2021 Dec; 29(2):341-351. PubMed ID: 34463929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
    Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
    Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
    Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients.
    Traversa A; Hammond DA; Peksa GD; DeMott JM
    J Pharm Pract; 2021 Dec; 34(6):882-887. PubMed ID: 32578474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.